Search

Displaying results 6271 - 6280 of 10000 in total
  1. Drug

    Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15714
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  2. Drug

    Fluprednidene

    go.drugbank.com/drugs/DB08970
    Experimental

    Fluprednidene is a corticosteroid.

    Categories: Corticosteroids, Moderately Potent (Group II)
  3. Drug

    GW-559090

    go.drugbank.com/drugs/DB06508
    Experimental

  4. Drug

    Edaglitazone

    go.drugbank.com/drugs/DB06519
    Investigational

  5. Drug

    Tramiprosate

    go.drugbank.com/drugs/DB06527
    Investigational

  6. Drug

    Dextofisopam

    go.drugbank.com/drugs/DB06582
    Investigational

  7. Drug

    Omiganan

    go.drugbank.com/drugs/DB06610
    Investigational

    Omiganan has been investigated for the treatment of Mupirocin-resistant MRSA skin infections.

  8. Drug

    Alipogene tiparvovec

    go.drugbank.com/drugs/DB13521
    Approved

    It is being investigated for the treatment of lipoprotein lipase (LPL) deficiency.[A259796, A259801, A259806, A259811] … Alipogene tiparvovec is an adeno-associated viral vector of serotype 1-based gene therapy that delivers the Ser(447)X variant of the human lipoprotein lipase (LPL) gene.

  9. Drug

    Solcitinib

    go.drugbank.com/drugs/DB19856
    Investigational

    Solcitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Solcitinib is a Janus kinase inhibitor. … Solcitinib is under investigation in clinical trial NCT01777256 (An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184).

  10. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    The D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome. … Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.